Cresco Labs: Rescheduling Ushers in a New Era as Growth Initiatives Compound

Q1 2026 results mark a pivot from cost discipline to expansion, anchored by federal rescheduling and a Pennsylvania footprint build-out

CRLBF · Earnings Call · 2026-05-08

A Turning Point

Cresco Labs' first-quarter 2026 report reads as a deliberate transition. Revenue of $151 million, adjusted gross margin of 51%, and adjusted EBITDA of $33 million (22% margin) held within guidance, but the narrative was not about the quarter—it was about the runway. The company framed Q1 as the baseline for a year of growth initiatives, citing its exit from California and Michigan's excise-tax disruption as temporary drags. "We started 2026 with a distinct plan, build for growth from a scaled foundation and go deeper in markets that have structural advantages," said CEO Charles Bachtell, “all while maintaining margin and cost discipline.” — Charles Bachtell, Chief Executive Officer and Co-Founder · 2026-05-08 The market's focus, however, has shifted to what happens next. Rescheduling—moving medical cannabis from Schedule I to Schedule III—is the single most consequential catalyst the industry has seen, and management's tone reflected both urgency and careful positioning. “Moving state-legal medical cannabis from Schedule I to Schedule III is the most consequential reform we've seen,” — Charles Bachtell, Chief Executive Officer and Co-Founder · 2026-05-08 Bachtell added, calling it a win for patients and a step toward normalization. The company is already thinking through the implications: removal of 280E, expanded capital access, and a more durable regulatory foundation.

Rescheduling and Normalization

The rescheduling theme has been building for months, but this call marked a clear shift from speculation to active planning. When asked about the phased approach and retrospective 280E relief, Bachtell acknowledged the uncertainty but remained constructive: "It is still a variable," he said, “but we're coming at it from the perspective of we did not have rescheduling or that encouragement 20 days ago.” — Charles Bachtell, Chief Executive Officer and Co-Founder · 2026-05-08 That pragmatism—building strategy for a world without reform while positioning for it—defines Cresco's approach. The company also reiterated its expectations for Q2, with CFO Sharon Schuler guiding for

Q2 revenue to increase approximately 10% sequentially
Sharon Schuler, Chief Financial Officer · 2026-05-08

as new stores and integration efforts contribute. This is a marked departure from prior calls, where the tone was more defensive. In the Q4 2025 call (March 2026), management emphasized M&A opportunism and operational efficiency, but rescheduling was not yet front and center. Now it is. The keyword trajectory for CRLBF shows "rescheduling" and "normalization" as fresh, high-momentum terms, absent from earlier quarters—a clear signal that the strategic narrative has shifted.

Pennsylvania and the Retail Expansion

The most concrete growth move is the pending acquisition of nine Pennsylvania dispensaries, already operating under a management services agreement (MSA). This brings Cresco's total footprint in the state to 27 stores, cementing its position as the #1 branded share operator in the second-largest medical market. "We've found, as others have, a lot of success in operating and competing in a state where you can build that type of scale," “Bachtell noted” — Charles Bachtell, Chief Executive Officer and Co-Founder · 2026-05-08—though that quote is from the current call, it echoes themes from prior quarters where management repeatedly highlighted the value of scale in limited-license states. The company also completed two Ohio store openings and reached its first Kentucky harvest, with branded products expected to reach patients in Q2. The Pennsylvania deal is particularly strategic because it positions Cresco for a likely adult-use catalyst in the state. Management flagged that the transaction "builds on our leading position... further preparing us for a likely adult-use catalyst," and expressed confidence in converting the stores to higher productivity over time. This is part of a broader pattern: rather than entering new states, Cresco is doubling down on base business strengths—cultivation yields, potency, and retail execution. In Ohio, border-market stores continue to outperform, and in Florida, share gains stem from improved flower potency and yields.

Outlook and the Path Forward

The company's guidance for Q2—revenue up ~10% sequentially, gross margins of 48%–50%, and adjusted EBITDA margin near 21%—relies on the stabilization of Michigan and the contribution of 11 new stores. Management acknowledged that Michigan remains a challenge (less than 3% of revenue) but noted that "the rate of challenge is getting better." “We are encouraged by what we will see in Michigan and where we can find growth elsewhere in our portfolio,” — Greg Butler, President · 2026-05-08 said President Greg Butler. Looking ahead, the biggest swing factor remains federal reform. Cresco is evaluating structures that could benefit from rescheduling, including tax relief and potential export avenues, but is intentionally measured: "We are definitely in learning and evaluation mode," Bachtell said. The company's cash position ($67 million) and lean cost structure provide flexibility, but the real upside lies in the optionality created by rescheduling—removing 280E alone could materially improve margins. As Charlie concluded, "Cresco is more focused, more efficient and structurally stronger than a year ago," and the pieces are now in place for a sustained growth phase. For investors, the call was a clear signal: the company has shifted from survival to offense, and the catalyst is just beginning to unfold.